Sheng et al. [34], in a phase IB trial limited to the Asian population, demonstrated that the combination of toripalimab (anti-PD-1) plus axitinib (a VEGF tyrosine kinase inhibitor) was well tolerated and had promising antitumor activity in patients with metastatic MM. The gene discussed is PDCD1; the disease is Miyoshi myopathy.